Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2001-05-01
2002-05-07
Davis, Zinna Northington (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C546S337000, C548S205000, C548S338500, C548S494000, C560S024000, C560S038000, C562S443000, C564S155000
Reexamination Certificate
active
06384220
ABSTRACT:
BACKGROUND OF THE INVENTION
Glucokinase (GK) is one of four hexokinases found in mammals [Colowick, S. P., in
The Enzymes
, Vol. 9 (P. Boyer, ed.) Academic Press, New York, N.Y., pages 1-48, 1973]. The hexokinases catalyze the first step in the metabolism of glucose, i.e., the conversion of glucose to glucose-6-phosphate. Glucokinase has a limited cellular distribution, being found principally in pancreatic &bgr;-cells and liver parenchymal cells. In addition, GK is a rate-controlling enzyme for glucose metabolism in these two cell types that are known to play critical roles in whole-body glucose homeostasis [Chipkin, S. R., Kelly, K. L., and Ruderman, N. B. in
Joslin's Diabetes
(C. R. Khan and G. C. Wier, eds.), Lea and Febiger, Philadelphia, Pa., pages 97-115, 1994]. The concentration of glucose at which GK demonstrates half-maximal activity is approximately 8 mM. The other three hexokinases are saturated with glucose at much lower concentrations (<1 mM). Therefore, the flux of glucose through the GK pathway rises as the concentration of glucose in the blood increases from fasting (5 mM) to postprandial (≈10-15 mM) levels following a carbohydrate-containing meal [Printz, R. G., Magnuson, M. A., and Granner, D. K. in
Ann. Rev. Nutrition
Vol. 13 (R. E. Olson, D. M. Bier, and D. B. McCormick, eds.), Annual Review, Inc., Palo Alto, Calif., pages 463-496, 1993]. These findings contributed over a decade ago to the hypothesis that GK functions as a glucose sensor in &bgr;-cells and hepatocytes (Meglasson, M. D. and Matschinsky, F. M.
Amer. J. Physiol
. 246, E1-E13, 1984). In recent years, studies in transgenic animals have confirmed that GK does indeed play a critical role in whole-body glucose homeostasis. Animals that do not express GK die within days of birth with severe diabetes while animals overexpressing GK have improved glucose tolerance (Grupe, A., Hultgren, B., Ryan, A. et al., Cell 83, 69-78, 1995; Ferrie, T., Riu, E., Bosch, F. et al.,
FASEB J
., 10, 1213-1218, 1996). An increase in glucose exposure is coupled through GK in &bgr;-cells to increased insulin secretion and in hepatocytes to increased glycogen deposition and perhaps decreased glucose production.
The finding that type II maturity-onset diabetes of the young (MODY-2) is caused by loss of function mutations in the GK gene suggests that GK also functions as a glucose sensor in humans (Liang, Y., Kesavan, P., Wang, L. et al.,
Biochem. J
. 309, 167-173, 1995). Additional evidence supporting an important role for GK in the regulation of glucose metabolism in humans was provided by the identification of patients that express a mutant form of GK with increased enzymatic activity. These patients exhibit a fasting hypoglycemia associated with an inappropriately elevated level of plasma insulin (Glaser, B., Kesavan, P., Heyman, M. et al.,
New England J. Med
. 338, 226-230, 1998). While mutations of the GK gene are not found in the majority of patients with type II diabetes, compounds that activate GK and, thereby, increase the sensitivity of the GK sensor system will still be useful in the treatment of the hyperglycemia characteristic of all type II diabetes. Glucokinase activators will increase the flux of glucose metabolism in &bgr;-cells and hepatocytes, which will be coupled to increased insulin secretion. Such agents would be useful for treating type II diabetes.
SUMMARY OF THE INVENTION
This invention provides a compound, comprising an amide of the formula:
wherein X is —O— or
R is a heteroaromatic ring, connected by a ring carbon atom, which contains from 5 to 6 ring members with from 1 to 3 heteroatoms selected from the group consisting of oxygen, sulfur or nitrogen, aryl containing 6 or 10 ring carbon atoms, aryl fused with a heteroaromatic ring which contains from 5 to 6 ring members with 1 to 3 heteroatoms in the ring being selected from the group consisting of nitrogen, oxygen or sulfur, a saturated 5- or 6-membered cycloheteroalkyl ring which contains from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, or a cycloalkyl ring having 5 or 6 carbon atoms; R
1
is a cycloalkyl ring having from 5 or 6 carbon atoms; R
2
is
a five- or six-membered heteroaromatic ring connected by a ring carbon atom to the amide group shown, which contains from 1 to 3 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen with a first heteroatom being nitrogen adjacent to the connecting ring carbon atom, said heteroaromatic ring being unsubstituted or monosubstituted at a position on a ring carbon atom other than adjacent to said connecting carbon atom with a substituent selected from the group consisting of lower alkyl,
—(CH
2
)
n
—OR
6
,
n is 0, 1, 2, 3 or 4; y and z are independently 0 or 1; R
3
is hydrogen, lower alkyl or
R
6
, R
7
and R
8
are independently hydrogen or lower alkyl; p is an integer from 0 to 5; and * denotes the asymmetric carbon atom center; or a pharmaceutically acceptable salt thereof.
The compounds of formula I are glucokinase activators are useful for increasing insulin secretion in the treatment of type II diabetes.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of formula I have the following embodiments
wherein
R, R
1
, R
3
, X, y, n and z are as above;
R
4
is a five- or six-membered heteroaromatic ring connected by a ring carbon atom to the amide group shown, which heteroaromatic ring contains from 1 to 3 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen with a first heteroatom being nitrogen adjacent to the connecting ring carbon atom, said heteroaromatic ring being unsubstituted or monosubstituted at a position on a ring carbon atom other than adjacent to said connecting carbon atom with a substituent selected from the group consisting of lower alkyl,
—(CH
2
)
n
—OR
6
,
n is 0, 1, 2, 3 or 4;
R
6
, R
7
and R
8
are independently hydrogen or lower alkyl;
or a pharmaceutically acceptable salt thereof.
In the compound of formulae I, IA and IB, the “*” designates the asymmetric carbon atom in this compound with the R optical configuration being preferred. The compounds of formula I may be present in the pure R form or as a racemic or other mixtures of compounds having the R and S optical configuration at the asymmetric carbon shown. The pure R enantiomers are preferred.
As used throughout this application, the term “lower alkyl” includes both straight chain and branched chain alkyl groups having from 1 to 7 carbon atoms, such as methyl, ethyl, propyl, isopropyl, preferably methyl and ethyl. As used herein, the term “halogen or halo” unless otherwise stated, designates all four halogens, i.e. fluorine, chlorine, bromine and iodine.
R can be any five- or six-membered saturated cyclic heteroalkyl ring containing from 1 to 2 heteroatoms selected from the group consisting of sulfur, oxygen or nitrogen. Any such five- or six-membered saturated heterocyclic ring can be used in accordance with this invention. Among the preferred rings are morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, etc.
As used herein, the term “aryl” signifies “polynuclear” and mononuclear unsubstituted aromatic hydrocarbon groups such as phenyl or naphthyl containing either 6 or 10 carbon atoms.
The heteroaromatic ring defined by R, R
2
and R
4
can be five- or six-membered heteroaromatic ring having from 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur which is connected by a ring carbon to the remainder of the molecule as shown. The heteroaromatic ring defined by R
2
and R
4
contains a first nitrogen heteroatom adjacent to the connecting ring carbon atom and if present, the other heteroatoms can be oxygen, sulfur, or nitrogen. Among the preferred heteroaromatic rings include pyridinyl, pyrimidinyl and thiazolyl. On the other hand, the heteroaromatic ring defined by R need not contain a nitrogen heteroatom. These heteroaromatic rings which constitute R
2
or R
4
are connected via a ring carbon atom to the amide group to form the amides
Corbett Wendy Lea
Haynes Nancy-Ellen
Sarabu Ramakanth
Davis Zinna Northington
Dawson Arthur D.
Hoffmann-La Roche Inc.
Johnston George W.
Rocha-Tramaloni Patricia S.
LandOfFree
Para-aryl or heterocyclic substituted phenyl glucokinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Para-aryl or heterocyclic substituted phenyl glucokinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Para-aryl or heterocyclic substituted phenyl glucokinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2878179